Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
Key Highlights
- ➤Galectin will deliver three belapectin analyses at AASLD Liver Meeting 2026
- ➤FDA receives registrational Phase 3 protocol for belapectin in MASH cirrhosis
- ➤Presentations analyze noninvasive variceal-development risk from NAVIGATE and GT-026 trials
- ➤ANTICIPATE-NASH analysis selected for oral presentation at AASLD
Expert Statements
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
“We are excited to have our ANTICIPATE-NASH analysis selected for oral presentation and the recognition of our Baveno and ELF analysis as a Poster of Distinction. These selections reflect not only the depth of the NAVIGATE trial datasets but also underscores the importance of non-invasive assessments in diagnosis of portal hypertension in patients with MASH cirrhosis who are at increased risk of developing serious complications such as varices. This represents the fourth consecutive major liver meeting where the Company has been selected for an oral presentation, and I want to thank our entire team led by Dr. Khurram Jamil, our Chief Medical Officer, for their efforts in this achievement. We have also submitted the registrational Phase 3 protocol, an important step forward in the advancement of our belapectin program for patients who today have no approved treatment options”
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.
In addition, the Company also announced today that it has submitted a registrational protocol for the Phase 3 trial of belapectin for the prevention of disease progression in patients with MASH cirrhosis and portal hypertension to the U.S. Food and Drug Administration (FDA).
Get started
Create a free account to read the full story.